Search Bar & Filters
Found 79 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying calderasib alone and in combination with cetuximab to treat advanced solid tumors in people with the KRAS G12C mutation. The study aims to find out how many patients respond to these treatments and to evaluate their safety and tolerability. This phase 2 trial is tumor-agnostic, meaning it includes various solid tumors except colorectal cancer that have progressed despite standard treatment. Participants receive calderasib by mouth, either alone or with cetuximab given by intravenous infusion every two weeks. There is no set maximum number of treatment cycles, and participants continue until they meet criteria to stop treatment. The study is randomized and open-label, comparing the two treatment approaches in parallel groups. During the study, participants will be monitored for tumor response, adverse events, and reasons for discontinuing treatment over about 76 months. Researchers will assess progression-free survival, duration of response, and overall survival. Safety evaluations and regular clinical visits will support ongoing monitoring throughout the trial.
Actively Recruiting
Researchers are evaluating treatments for high-grade serous and certain other types of ovarian cancer that tend to grow and spread quickly. This study focuses on advanced cancers that started in the ovaries, lining of the belly, or fallopian tubes. The trial aims to assess the safety, tolerability, and response of a study drug called Raludotatug Deruxtecan R-DXd, which is an antibody drug conjugate designed to target and destroy cancer cells. This research includes a dose escalation phase followed by an expansion phase using the recommended dose. Participants will receive R-DXd through intravenous infusions every three weeks, often combined with other anticancer treatments such as carboplatin, paclitaxel, bevacizumab, pembrolizumab, or MK-2010. These combinations vary across different groups in the study, with some receiving up to six cycles of chemotherapy drugs over approximately four months, and others receiving immunotherapy or targeted therapy for longer periods, up to two years. The study allows continued treatment with R-DXd until disease progression or discontinuation. During the trial, participants will undergo regular clinical assessments including imaging scans to measure tumor response, monitoring for side effects, and laboratory tests. The main outcomes include tracking dose-limiting toxicities, adverse events, treatment discontinuations due to side effects, objective tumor response, and progression-free survival. Follow-up may continue for up to several years to evaluate longer-term effects and survival. The total duration of participation depends on treatment response and tolerability.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.
Actively Recruiting
Researchers are conducting a Phase 1, first in human, open-label trial to evaluate ALX2004, an antibody drug conjugate targeting EGFR, in participants with advanced or metastatic selected solid tumors. The study focuses on patients with non-small cell lung cancer NSCLC, head and neck squamous cell carcinoma HNSCC, esophageal squamous cell carcinoma ESCC, and colorectal cancer CRC who have received prior treatments. This research aims to assess the safety, dosing, and effectiveness of ALX2004 in these advanced cancers. The study includes three phases Phase 1a dose escalation to find safe dose levels, dose exploration to refine dosing in specific tumor types, and Phase 1b dose expansion where participants receive the recommended phase 2 dose. ALX2004 is administered by intravenous infusion. Participants will be enrolled sequentially into escalating dose levels initially, followed by enrollment into selected dose levels for further evaluation. Participants will undergo assessments for dose limiting toxicities, adverse events, and tumor response using RECIST criteria up to two years after dosing. Pharmacokinetics including drug concentration and clearance will be measured along with immunogenicity and survival outcomes. The study involves monitoring safety and treatment effects over time, with expected enrollment of up to 170 patients and a study duration extending to late 2027.
Actively Recruiting
Researchers are studying MEN2312, a lysine acetyltransferase 6 KAT6 inhibitor, in adults with advanced breast cancer that is not curable. This first-in-human, phase 1 study evaluates MEN2312 alone and in combination with elacestrant to understand its safety and determine the best dose. Participants have specific genetic alterations in their tumors and have received prior endocrine therapy and cyclin-dependent kinase 4 and 6 inhibitor treatment. Participants will be randomly assigned to receive either MEN2312 by itself or MEN2312 combined with elacestrant, both given as oral tablets. The study follows a sequential design and aims to identify dose-limiting toxicities and recommend the phase 2 dose over several months of treatment. This includes monitoring drug levels in the body and how the body processes the medications. During the study, participants will have regular assessments to monitor side effects, tumor response, and overall health. These include evaluating the number of dose-limiting toxicities within the first 28 days and tracking response rates, progression-free survival, and overall survival for up to nine months after treatment ends. Researchers will also measure drug concentration and excretion to better understand the treatment effects and safety over time.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of IMP1734, a PARP1 selective inhibitor, in people with advanced solid tumors. This study includes patients with breast cancer, metastatic prostate cancer, ovarian cancer, and other solid tumors who have previously received certain treatments. The goal is to find an optimal dose for future clinical development by studying how the drug affects the body and how the body processes it. The study has two parts Part 1 involves gradually increasing doses of IMP1734 given as a daily oral tablet to identify the highest safe dose or maximum achievable dose. This includes testing the drug alone and in combination with other treatments for specific cancers like metastatic prostate, ovarian, and breast cancer. Part 2 focuses on refining the dose to find the best amount for future studies. Treatment can last up to three years after the first dose. Participants will be monitored closely with assessments of side effects, blood tests to study drug levels and effects, and evaluations of tumor response using standard criteria. Safety monitoring continues up to 30 days after the last dose. Researchers measure how well the drug is tolerated and its impact on the cancer over time. The total participation may extend up to three years, with ongoing evaluations during this period.
Actively Recruiting
Researchers are conducting a Phase 1 study to evaluate BHV-1530 alone and in combination with cemiplimab in adults with advanced or metastatic solid tumors. This first-in-human, open-label trial aims to determine the safety, dosing, and potential benefits of BHV-1530 for patients whose cancer has progressed after standard treatments or who have no other available therapies. The study focuses on specific cancers including urothelial cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma, especially those with certain genetic alterations. Participants will receive BHV-1530 as an intravenous infusion on Day 1 of each 21-day cycle, either alone or combined with cemiplimab given on the same schedule. The study includes dose escalation, expansion, and optimization phases to find the maximum tolerable dose and recommended dose range. Some groups may receive the drug alone, while others receive it combined with cemiplimab, with treatment continuing over multiple cycles as determined by the study protocol. During the trial, participants will have regular assessments to monitor safety and treatment effects, including tumor measurements according to RECIST 1.1 criteria and performance status evaluations. Researchers will collect tumor tissue samples, perform laboratory tests, and monitor drug levels in the blood. The main outcomes include determining optimal dosing, safety profile, and clinical benefit rates over an estimated 48 months. Participants health and response to treatment will be carefully followed throughout the study period.
Actively Recruiting
Researchers are evaluating PLN-101095 combined with pembrolizumab in adults with advanced or metastatic solid tumors that have progressed despite prior pembrolizumab treatment. This Phase 1a1b open-label study aims to assess the safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and early signs of antitumor activity of this combination in patients with documented resistance to immune checkpoint inhibitors. The study includes two parts Part 1 involves consecutive dose-escalation cohorts of PLN-101095 at varying doses 250 mg to 2000 mg, administered twice or three times daily combined with pembrolizumab given intravenously every three weeks. Part 2 expands dosing cohorts to evaluate the combination and PLN-101095 monotherapy in specific tumor types, including non-small cell lung cancer, clear cell renal cell carcinoma, and tumor mutational burden-high solid tumors. Participants undergo treatment cycles with regular safety and tumor assessments, including monitoring of side effects and drug levels. Researchers will measure outcomes such as safety and tolerability from first dose through 16 weeks post-treatment, as well as antitumor activity until disease progression or death. The study spans up to several years, with ongoing evaluations to understand the treatments effects and duration of response.
Actively Recruiting
Researchers are studying IAM1363 in a Phase 11b open-label trial involving participants with advanced cancers that have HER2 alterations. The study aims to evaluate the safety and early effectiveness of IAM1363 in these cancers, including cases with brain metastases. It is a multi-center trial sponsored by Iambic Therapeutics, Inc, designed to find appropriate dosing and assess potential benefits in patients with relapsed or refractory HER2-altered tumors. The study consists of four parts initial dose escalation of IAM1363 given alone, dose optimization to refine dosing, dose expansion to test the selected doses in specific tumor types, and combination cohorts where IAM1363 is given with other anti-cancer agents. Participants receive IAM1363 orally in 14- or 21-day cycles either alone or combined with drugs such as capecitabine, trastuzumab, zanidatamab, T-Dxd, pembrolizumab, carboplatin, or pemetrexed. Participants will be monitored through various assessments including measuring side effects, laboratory tests, electrocardiograms, and scans to evaluate tumor response. Researchers will track dose limiting toxicities, adverse events, pharmacokinetics, and tumor response rates over the course of the trial and follow-up, which may last up to 46 months. Safety and treatment modifications are closely observed through and after treatment completion.
Actively Recruiting
Researchers are conducting a Phase 12, first-in-human, open-label study of BHV-1510, an antibody-drug conjugate targeting Trop-2, in participants with advanced solid tumors that have been previously treated. The study aims to evaluate the safety, tolerability, and preliminary effectiveness of BHV-1510 alone and in combination with cemiplimab, an anti-cancer agent, in patients with tumors resistant to standard therapies. This trial is multicenter and sponsored by Biohaven Therapeutics Ltd. The study has two parts Phase 1 includes dose escalation to determine safe and tolerable doses of BHV-1510 as monotherapy and combined with cemiplimab, identifying recommended doses for expansion and maximum tolerated doses. Phase 2 expands to evaluate preliminary effectiveness in different tumor cohorts using the established doses. BHV-1510 is administered intravenously in different schedules every 2 or 3 weeks, sometimes with doses on Day 1 and Day 8, and cemiplimab is given as a 350mg IV infusion every 3 weeks, alone or in combination. Participants will undergo regular assessments including monitoring adverse events throughout the study, pharmacokinetic blood sampling at specific time points, and tumor response evaluations using established criteria. The study tracks objective response rates, duration of response, and survival outcomes over an average of 47 months. Safety, drug levels, and immune responses are closely monitored. The total trial duration may extend up to approximately 47 months, ensuring comprehensive evaluation and follow-up of participant outcomes.
1-10 of 79
1